Phaseline

Companies › Renibus Therapeutics

Renibus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Veverimer
Patented resin-based medication that buffers acid in the gastrointestinal tract
–Phase 3CKDJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07355062VeverimerPhase 3CKDMetabolic and endocrineJun 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Fresenius Kabi Chendu DIAO Pharmaceutical Group Kowa Company Azafaros Waterstone Pharmaceutical (Wuhan)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.